IDoser: Improving individualized dosing policies with clinical practice and machine learning

Author:

Correa NuriaORCID,Cerquides JesusORCID,Vassena RitaORCID,Popovic MinaORCID,Arcos Josep LluisORCID

Abstract

AbstractBackgroundFinding the correct drug dose for a specific condition is a key step in many treatments, and failing to do so can lead to deleterious consequences to patient health. Clinical protocols are derived from drug development phase prospective trials. While carefully designed, these often do not include all potential patients, comorbidities or clinical outcomes, ultimately leading to sub-optimal dosing policies. Observational datasets provide real-world information that cannot be substituted with data collected in a controlled environment. Several published methodologies have applied observational datasets for the development of clinical protocols, however these are only applicable whenever these datasets are varied and complete. Often, clinical observational datasets do not comply with these requirements. Computational methods can and should exploit field knowledge to address weaknesses associated with clinical observational data.MethodsThis paper proposes IDoser, a core dosing model that links drug dose to relevant covariates via a set of coefficients, and includes a loss function to codify needed assumptions and requirements. Coordinate descent is used to obtain a fitted model with minimal loss. The loss function is also used to measure performance when validating the model with unseen data. Our proposal is validated using the case of follicle stimulating hormone (FSH) dosing for controlled ovarian stimulation (COS).ResultsThe proposed Individualized Doser (IDoser) achieved significant improvements when loss values were compared to observed clinical practice and a selected literature benchmark and during the validation phase.ConclusionsThis methodology constitutes a simple but effective method to bridge the gap between current clinical dosing policies and gold policies based on the true underlying and often unknown dose-response functions.

Publisher

Cold Spring Harbor Laboratory

Reference44 articles.

1. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials

2. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles

3. Arce, J.C. , Klein, B.M. , Erichsen, L. , 2016. Using amh for determining a stratified gonadotropin dosing regimen for IVF/ICSI and optimizing outcomes. Anti-Mullerian Hormone: Biology, Role in Ovarian Function and Clinical Significance, 83–102.

4. From Real‐World Patient Data to Individualized Treatment Effects Using Machine Learning: Current and Future Methods to Address Underlying Challenges

5. Bica, I. , Jordon, J. , 2020. Estimating the Effects of Continuousvalued Interventions using Generative Adversarial Networks arXiv:arXiv:2002.12326v2.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3